What is Crossbow Therapeutics?
Crossbow Therapeutics is a biotechnology firm dedicated to pioneering advanced antibody-based therapies for oncological conditions. The company is recognized for its expertise in engineering novel molecules designed to mimic natural immune responses, thereby enhancing the precision and efficacy of cancer treatments. By focusing on immunotherapy and precision medicine, Crossbow Therapeutics aims to broaden the accessibility of advanced therapies and contribute to improved patient outcomes in oncology.
How much funding has Crossbow Therapeutics raised?
Crossbow Therapeutics has raised a total of $187.3M across 3 funding rounds:
Series A
$80M
Private Equity
$30.3M
Series B
$77M
Series A (2023): $80M with participation from Polaris Partners, Eli Lilly and Company Pvt, and BVF Partners
Private Equity (2025): $30.3M, investors not publicly disclosed
Series B (2026): $77M supported by LifeLink Ventures, Lilly, Pfizer, BVF Partners, Polaris Partners, Sixty Degree Capital, MPM BioImpact, Taiho Ventures, and Mirae Asset Venture Investment
Key Investors in Crossbow Therapeutics
LifeLink Ventures
LifeLink Ventures is a Barcelona-based venture capital firm specializing in early-stage health and biotech companies, focusing on addressing global health challenges through strategic capital deployment.
Lilly
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and commercialization of prescription medicines across key therapeutic areas including oncology and immunology.
Pfizer
Pfizer is a biopharmaceutical company that researches, develops, manufactures, and markets medicines and vaccines, with a focus on oncology, inflammation, and immunology to help manage disease worldwide.
What's next for Crossbow Therapeutics?
The recent major strategic investment positions Crossbow Therapeutics for accelerated growth and the advancement of its therapeutic pipeline. With significant backing, the company is poised to further its research and development efforts, potentially expanding its clinical trials and manufacturing capabilities. This infusion of capital is expected to fuel innovation in engineered antibody design and immunotherapy, reinforcing Crossbow's role as a key player in the competitive landscape of cancer drug development. The company's trajectory suggests a focus on scaling operations and bringing its promising treatments closer to market.
See full Crossbow Therapeutics company page
